Figure - available from: Infection and Drug Resistance
This content is subject to copyright. Terms and conditions apply.
Source publication
Background
Tuberculosis (TB) is still the single pathogen infectious disease with the largest number of deaths worldwide. The relationship that intestinal microbiota disorder and de novo fatty acid synthesis metabolism have with disease progression in multi-drug resistant TB (MDR-TB) has not yet been fully studied.
Objective
To investigate the eff...
Similar publications
The human gut bacteriome is believed to have pivotal influences on human health and disease while the particular roles associated with the gut phageome have not been fully characterized yet with few exceptions. It is argued that gut microbiota can have a potential role in autism spectrum disorders (ASD). The public microbiota database of ASD and ty...
Citations
... Alterations in the gut microbiota of DR-TB-treated patients have been reported in terms of overall decrease in alpha diversity that can last for years after treatment completion (Wang et al., 2020;Shi et al., 2021). In particular, an increase of Enterobacteriaceae is seen from healthy to RR and MDR, along with a decrease in members of the phylum Actinobacteria and Firmicutes in MDR patients (Wang et al., 2020;Shi et al., 2022). Furthermore, phylum Verrucomicrobia was found as a predominant component in Pre-XDR-TB, whereas it is almost undetectable in healthy, RR or MDR individuals (Shi et al., 2022). ...
... In particular, an increase of Enterobacteriaceae is seen from healthy to RR and MDR, along with a decrease in members of the phylum Actinobacteria and Firmicutes in MDR patients (Wang et al., 2020;Shi et al., 2022). Furthermore, phylum Verrucomicrobia was found as a predominant component in Pre-XDR-TB, whereas it is almost undetectable in healthy, RR or MDR individuals (Shi et al., 2022). On the other hand, studies on the macaque model have shown an increase in Proteobacteria in RR and MDR but not in Pre-XDR-TB or healthy controls (Namasivayam et al., 2019). ...
... Moreover, members of the Bacteroidetes phylum were only found in healthy individuals. Gut-derived metabolites, such as SCFAs, tryptophan and secondary bile acids, decreased from MDR to Pre-XDR and RR to healthy participants, underscoring a complex interaction between the microbiota and immune system (Shi et al., 2022). Studies of monotherapies, although not in TB patients, particularly cycloserine treatment, a group B drug, reduces Bifidobacterium species and other butyrate producers in the gut microbiota (Minichino et al., 2021). ...
Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis (MTB) that remains a significant global health challenge. The extensive use of antibiotics in tuberculosis treatment, disrupts the delicate balance of the microbiota in various organs, including the gastrointestinal and respiratory systems. This gut-lung axis involves dynamic interactions among immune cells, microbiota, and signaling molecules from both organs. The alterations of the microbiome resulting from anti-TB treatment can significantly influence the course of tuberculosis, impacting aspects such as complete healing, reinfection, and relapse. This review aims to provide a comprehensive understanding of the gut-lung axis in the context of tuberculosis, with a specific focus on the impact of anti-TB treatment on the microbiome.
